Weight-Loss Surgery Outperforms GLP-1 Drugs for Heart Health in Type 2 Diabetes

For individuals with type 2 diabetes and obesity, metabolic and bariatric surgery (MBS) offers superior long-term cardiovascular protection compared to glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a recent meta-analysis published in Obesity Surgery.

The Findings

The meta-analysis, which encompassed data from 11 studies and nearly 20,000 patients, revealed that MBS was associated with a 52% relative risk reduction for major adverse cardiovascular events (MACE) and all-cause mortality when compared to GLP-1 RA therapy. This benefit remained consistent across both randomized controlled trials (RCTs) and observational cohorts, even when accounting for variations between studies.

Study Details

Researchers, led by Joshua Chadwick from the Indian Council of Medical Research, analyzed studies involving patients from the United States, China, Italy, Sweden, Israel, Australia, and Taiwan. The most common MBS procedures included Roux-en-Y gastric bypass and sleeve gastrectomy. Common GLP-1 drugs used in the studies were semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity).

GLP-1s as Adjunct Therapy

While MBS demonstrates greater cardiovascular benefits, GLP-1 analogues can still play a role in managing obesity and related conditions. Research indicates they are often used as adjunct therapies to bariatric surgery, both before and after the procedure, to address inadequate weight loss or weight regain and the recurrence of obesity-related comorbidities.

Implications for Patient Care

Although both MBS and GLP-1 RAs are effective strategies for improving metabolic outcomes and reducing cardiovascular risk in individuals with obesity and type 2 diabetes, their risk-benefit profiles differ. This meta-analysis provides valuable comparative evidence regarding long-term outcomes, suggesting that MBS may be the preferred option for maximizing cardiovascular protection in this patient population.

Key Takeaways

• Metabolic and bariatric surgery (MBS) provides greater cardiovascular protection than GLP-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes and obesity.
• MBS was associated with a 52% relative risk reduction in major adverse cardiovascular events (MACE) and all-cause mortality compared to GLP-1 RAs.
• Common MBS procedures include Roux-en-Y gastric bypass and sleeve gastrectomy.
• GLP-1 analogues can be used as adjunct therapies to bariatric surgery.